Skip to content
Case Study

Pharmaceutical Supply Chain Risk

From Hidden Dependencies to
Defensible, Revenue-Protected Decisions

Mapped 300+ suppliers across 4 tiers in under 3 days—identifying critical single points of failure and quantifying nine-figure revenue exposure.

 

Client Challenge

A Fortune 500 pharmaceutical manufacturer experienced a critical supplier disruption that resulted in significant revenue loss for a key product line and weakened its competitive position in regulated markets.

pharma-2

Despite operating in a highly controlled environment, critical dependencies beyond tier 1 were not fully visible, leaving the organisation exposed to:

  • Single points of failure across APIs and components 
  • Long supplier replacement cycles due to regulatory constraints 
  • Inability to respond quickly to disruptions
  • Loss of market share during supply shortages 

Investigations were slow, resource-intensive, and heavily reliant on manual processes, often taking weeks or months to fully assess impact.

At the executive level, there was no clear, defensible link between supply chain disruption and revenue impact, limiting the ability to act with confidence or justify mitigation decisions.

Scope and Objectives

Goal: Rapidly discover, visualize, and mitigate supply chain risks across two high-value product lines—while quantifying financial exposure and improving audit readiness.

Key Inputs

  • Bills of Materials (BOMs) for two products
  • Partial list of global operating sites
  • Partial tier 1 supplier data
 
Case Study

The Approach

 
1. Discover & Visualize
  • Ingested BOMs and supplier data to map tier 1 through tier 4 suppliers and dependencies
  • Inferred production geographies and supply flows across regulated components
  • Delivered a live, user-friendly, human-centric interactive canvas of the full value chain
pharma-cs-1
 
2. Identify Weak Spots
  • Highlighted single points of failure and supplier concentration risks
  • Enriched supplier network with financial, geographic, and operational risk indicators
  • Identified critical vulnerabilities across APIs and regulated inputs
  • Quantified potential revenue exposure tied to key nodes 
pharma-cs-2-1
 
3. Mitigate
  • Surfaced similarly qualified alternative suppliers 
  • Enabled data-driven mitigation strategies aligned with regulatory and recertification constraints 
  • Supported faster decision-making on supplier replacement and diversification  
pharma-cs-3
 
Outcomes
  • End-to-end visibility across 300+ entities spanning multiple tiers 
  • Identification of critical vulnerabilities and single points of failure 
  • Quantified >€100M revenue exposure linked to key dependencies
  • Reduced time to impact assessment from ~6–8 weeks to <5 days
  • Improved ability to make audit-ready, defensible sourcing decisions 
 

Why Attaima?

  • Speed at scale: Delivered multi-tier visibility in days, not months
  • Deep tier insight: Uncovered dependencies beyond tier 1 in regulated environments
  • Financial linkage: Connected supply chain disruption directly to revenue impact
  • Regulatory-ready: Supported compliant, defensible decision-making
  • Continuous monitoring: Enabled early detection of emerging risks

Next steps / ongoing work

  • Expand coverage across additional product lines and global operations
  • Integrate continuous monitoring across suppliers and geographies
  • Enhance scenario modelling to simulate disruption and mitigation strategies
pharma-white
" We moved from reactive investigations to proactive, financially grounded decision-making across our supply chain. "
– Global Supply Chain Leader
Pharmaceutical Manufacturer

Emblem

Learn more about how attaima can help your pharma value chain